A phase II study of single agent mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in patients with diffuse large cell B-cell (DLBCL) and follicular (FL) lymphomas.
Michael Crump
Research Funding - MethylGene
Charalambos Andreadis
Research Funding - MethylGene
Sarit E. Assouline
Research Funding - MethylGene
David Rizzieri
Research Funding - MethylGene
Amanda Copeland
Research Funding - MethylGene
Richard H. C. Van Der Jagt
Research Funding - MethylGene
Susan Fox
Research Funding - MethylGene
Gregory K. Reid
Employment or Leadership Position - MethylGene
Jeffrey M. Besterman
Employment or Leadership Position - MethylGene
Stock Ownership - MethylGene
Robert E. Martell
Stock Ownership - MethylGene
Research Funding - MethylGene
Anas Younes
Honoraria - MethylGene
Research Funding - MethylGene